ORIGINAL ARTICLE |
|
Year : 2015 | Volume
: 8
| Issue : 3 | Page : 334-336 |
|
Screening for metallo-β-lactamase producing Pseudomonas aeruginosa in clinical isolates in a tertiary care hospital in North India
Sunite A Ganju, Ramesh Chand Guleria, Suruchi Bhagra, Anil K Kanga
Department of Microbiology, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India
Correspondence Address:
Sunite A Ganju House No 214/B, Sector 3, New Shimla, Shimla -171 009, Himachal Pradesh India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0975-2870.150506
|
|
Introduction: Pseudomonas aeruginosa has acquired a new metallo-β-lactamase (MBL) resistance gene responsible for increased resistance to fluoroquinolones, cephalosporins and carbapenems. Thus, it is essential to know the antibiotic sensitivity pattern and follow the antibiotic policy. Objectives: The objective of this study is to detect MBL production in clinical isolates by combined imipenem-ethylenediamine tetra acetic acid (IMP-EDTA) disc test. Materials and Methods: This study was conducted for a period of nine months from April 2011 to December 2011. A total of 66 consecutive isolates of P. aeruginosa were subjected to susceptibility testing by disc diffusion assay. IMP drug resistant strains were screened for MBL production by combined IMP-EDTA disc test. Results: Ciprofloxacin resistance was seen in 66.6% isolates followed by piperacillin in 51.5%. Resistance toward amikacin, ceftazidime, and cefoperazone were noted in 43.9%, 40.9%, and 37.8% isolates, respectively. In 37.8%, IMP resistance was observed. All IMP resistant strains (n = 25) were screened for MBL production. All the 25 isolates (100%) were MBL producers, exhibiting more than 7 mm zone size enhancement in IMP-EDTA combined disc test. Conclusion: Emergence of P. aeruginosa as MBL producer is becoming a therapeutic challenge. There is a need to implement routine antibiotic surveillance and judicious use of antibiotics. |
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|